Celyad Oncology (NASDAQ:CYAD – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday, Zacks.com reports. The firm presently has a $2.25 price target on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 7.66% from the company’s […]